. Author manuscript; available in PMC: 2012 Sep 1.

Published in final edited form as: Anticancer Drugs. 2011 Sep;22(8):794–800. doi: 10.1097/CAD.0b013e328346af0d

Table 2.

Toxicity and efficacy data of patients treated with Sunitinib according to creatinine clearance

CHARACTERISTICS	SUNITINIB
CHARACTERISTICS	CrCl ≤ 60 ml/min N=7	CrCl > 60 ml/min N=19
Skin Rash (mild – moderate) (Incl.Hand-foot syndrome)	2 (29%)	7 (37%)
Diarrhea (Grade 1- 2)	1 (14%)	7 (37%)
Infections	0	8 (42%)
Fatigue Mild Moderate Severe	0 5 (71%) 1 (14%)	5 (26%) 10 (53%) 2 (11%)
Drop in Ejection Fraction >15%	1/ 3^* (33%)	3/15^* (20%)
Decrease in CrCl Median drop in CrCl (ml/min)	1 (14%) 5	6 (32%) 15
Bleeding	1(14%)	2(11%)
Thyroid Dysfunction	3/5^* (60%)	2/8^* (25%)
Proteinuria	0/5^*	6/13^* (46%)
Median Systolic Blood Pressure prior to starting therapy (mm Hg) Median Diastolic Blood Pressure prior to starting therapy (mm Hg)	146 (99-153) 77 (50-88)	143 (114-180) 82 (61-100)
Median rise in Systolic BP during therapy Median rise in Diastolic BP during therapy	30mm 15mm	18mm 5mm
Dose interruption(s)	1 (14%)	6 (32%)
Dose reduction(s)	0	3 (16%)

Denominator indicates the number of patients tested if less than the total number